PLUS THERAPEUTICS, Inc. (PSTV): Price and Financial Metrics
GET POWR RATINGS... FREE!
PSTV Stock Price Chart Interactive Chart >
PSTV Price/Volume Stats
| Current price | $0.44 | 52-week high | $1.20 |
| Prev. close | $0.43 | 52-week low | $0.29 |
| Day low | $0.42 | Volume | 207,200 |
| Day high | $0.45 | Avg. volume | 402,917 |
| 50-day MA | $0.39 | Dividend yield | N/A |
| 200-day MA | $0.53 | Market Cap | 14.86M |
PLUS THERAPEUTICS, Inc. (PSTV) Company Bio
PLUS THERAPEUTICS, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops, and commercializes specialty novel therapeutics for the treatment of cancer and other life-threatening diseases. PLUS THERAPEUTICS operates in the States of Texas and California.
Latest PSTV News From Around the Web
Below are the latest news stories about PLUS THERAPEUTICS INC that investors may wish to consider to help them evaluate PSTV as an investment opportunity.
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent GlioblastomaFigure Initial treatment imaging from first patient treated in the ReSPECT-GBM Phase 2b trial AUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the first patient has been dosed in the ReSPECT-GBM Phase 2b dose expansion clinical trial evaluating rhenium (186Re) obisbemeda f |
Why Plus Therapeutics Inc. (NASDAQ: PSTV) Stock Shouldn’t Be Ignored In 2023In the last trading session, 1.23 million shares of the Plus Therapeutics Inc. (NASDAQ:PSTV) were traded, and its beta was 0.30. Most recently the company’s share price was $0.48, and it changed around $0.09 or 23.89% from the last close, which brings the market valuation of the company to $13.01M. PSTV currently trades at a … Why Plus Therapeutics Inc. (NASDAQ: PSTV) Stock Shouldn’t Be Ignored In 2023 Read More » |
Plus Therapeutics: Targeting Brain Cancer with Rifle-Shot PrecisionPlus Therapeutics, Inc. (Nasdaq: PSTV) specializes in targeted radiation treatments Rather than traditional radiation beams, Plus uses needle-sized applicators into brain fluid Focused on brain cancer which is difficult to […] |
Plus Therapeutics Inc. (NASDAQ:PSTV) Drops -3.46%, But Further Rally Could Be ImminentIn last trading session, Plus Therapeutics Inc. (NASDAQ:PSTV) saw 0.4 million shares changing hands with its beta currently measuring 0.36. Company’s recent per share price level of $0.30 trading at -$0.01 or -3.46% at ring of the bell on the day assigns it a market valuation of $9.99M. That closing price of PSTV’s stock is … Plus Therapeutics Inc. (NASDAQ:PSTV) Drops -3.46%, But Further Rally Could Be Imminent Read More » |
Was anything negative for Plus Therapeutics Inc. (PSTV) stock last session?In Monday’s session, Plus Therapeutics Inc. (NASDAQ:PSTV) marked $0.35 per share, down from $0.39 in the previous session. While Plus Therapeutics Inc. has underperformed by -9.95%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PSTV fell by -71.99%, with highs and lows ranging from $2.16 to […] |
PSTV Price Returns
| 1-mo | 33.33% |
| 3-mo | -10.20% |
| 6-mo | -8.56% |
| 1-year | -55.40% |
| 3-year | -80.62% |
| 5-year | -99.82% |
| YTD | 38.80% |
| 2022 | -69.81% |
| 2021 | -48.02% |
| 2020 | -15.83% |
| 2019 | -83.45% |
| 2018 | -90.33% |
Loading social stream, please wait...